Abstract:Background:This open, observational clinical study aimed to investigate the efficacy, safety and survival outcomes of neoadjuvant chemotherapy, neoadjuvant immunotherapy with(out) chemotherapy and neoadjuvant targeted therapy among resectable stage III non-small cell lung cancer (NSCLC) patients (NCT04197076) in real world. 48 of the 57 evaluable patients were included in this interim analysis.Methods:This study was conducted at Shanghai Chest Hospital and included eligible NSCLC patients who were 18 years or older and had resectable clinical stage III disease. Surgical resection was conducted after neoadjuvant chemotherapy (13 patients), immunotherapy with(out) chemotherapy (26 patients), and targeted therapy (9 patients). Disease-free survival (DFS) was evaluated as the primary endpoint. The secondary endpoint was pathological complete response (pCR) rate. Clinical response rate (cRR), related adverse events (AEs), surgical feasibility and pathological features were also discussed in this study.Results:Significant differences in DFS were noted between chemotherapy and immunotherapy [7.7 months (range, 3.1 to 23.2 months) vs. 9.6 months (range, 4.0 to 47.9 months); P=0.032], and between chemotherapy and targeted therapy [7.7 months (range, 3.1 to 23.2 months) vs. 13.2 months (range, 7.5 to 32.2 months); P=0.015], but not between immunotherapy and targeted therapy (P=0.500). Subgroup analysis also favored neoadjuvant immunotherapy and targeted therapy. 5 patients achieved pathological complete response (pCR), all of whom were in the neoadjuvant immunotherapy arm, leading to a pCR rate of 19.2% in this arm. Treatment-emergent adverse events (TEAEs) of over grade 3 occurred in 11 patients (19.3%), with 5 (29.4%) in the chemotherapy arm, 5 (16.7%) in the immunotherapy arm and 1 (10.0%) in the targeted therapy arm. One grade 4 and one grade 2 surgery-related serious adverse event occurred in the neoadjuvant chemotherapy and immunotherapy arm, respectively.Conclusion:In patients diagnosed with resectable stage III NSCLC, neoadjuvant immunotherapy and neoadjuvant targeted therapy were associated with significantly longer disease-free survival compared with neoadjuvant chemotherapy. Clinical and pathological response rates were also higher in the immunotherapy and targeted therapy arm. Adverse events were found to be manageable and similar across all three groups, and surgical feasibility favored immunotherapy or targeted therapy rather than chemotherapy.Clinical trial registration:https://clinicaltrials.gov/, identifier NCT04197076.

Clinical research of compound rhizoma smilacinus granule on treatment of non-small cell lung cancer in Ⅲ~Ⅳ stage

Clinical researches on Qiyeling Granule combined with chemotherapy in treating advanced non-small-cell lung cancer

Three Dimensional-conformal Radiotherapy Combined Concurrent Chemotherapy with Vinorelbine and Cisplatin for Stage Ⅲ Non-small Cell Lung Cancer

Clinical trial of Qiyeling granule in the treatment of advanced non-small-cell lung cancer

[A multicenter, large-sample, randomized clinical trial on improving the median survival time of advanced non-small cell lung cancer by combination of Ginseng Rg3 and chemotherapy]

Effect of Haishengsu Preparation Extracted from Tegillarca Granosa in Treatment of Intermediate and Late Non-Small-cell Lung Cancer (NSCLC) and Late Renal Cancer

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Shenlingcao Oral Liquid for Patients with Non-Small Cell Lung Cancer Receiving Adjuvant Chemotherapy after Radical Resection: A Multicenter Randomized Controlled Trial

Observation of Curative Effect of Combined 20(R) - Ginsenoside Rg3 with chemotherapy on nonsmall- cell Lung Cancers

[Treatment of Radical Resected NSCLC by Chinese Medicine Combined with Adjuvant Chemother- Apy: a Clinical Study].

Clinical research of combined xiaoaiping injection with chemotherapy on advanced non-small cell lung cancer

Clinical study on the treatment of non small cell lung cancer with NP chemotherapy regimen and brucea fruitwater in oil emulsion

Xiaoaiping Injection Combined with Cisplatin and Gemcitabine for Non-Small Cell Lung Cancer: A Clinical ObservationΔ

Clinical Efficacy of CT-guided 125 I Radioactive Seeds Implantation for Stage Ⅲ of Non-Small Call Lung Cancer

Efficacy and Safety Assessment of Intrathoracic Perfusion Chemotherapy Combined with immunological factor Interleukin-2 in the Treatment of Advanced Non-Small Cell Lung Cancer: A Retrospective Cohort Study

Study on Concomitant Radiotherapy and Chemotherapy Combinating with Endostatin for ⅢB and Ⅳ Stage Non-small Cell Lung Cancer

The Efficacy of Ginsenoside Rg3 Combined with First-line Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer in China: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

[Clinical Study of Integrative Treatment for Ninety-One Elderly Patients with Advanced Non-Small Cell Lung Cancer].

Results of Chemotherapy and Clinical Significance of Serum CRP and Alb in Patients of Metastatic Non-Small Cell Lung Cancer

An Open, Observational Clinical Study of Neoadjuvant Therapy in Resectable Stage III Non-Small Cell Lung Cancer.

A Meta-Analysis of Ginsenoside Rg3 for Non-Small Cell Lung Cancer